EVOLVE-205 / EvolveImmune Therap - LARVOL DELTA

EVOLVE205, a dual (2:1) CD20 targeted CD3 trispecific T cell engager with CD2 costimulation for the treatment of B cell malignancies and B cell autoimmune disorders (AACR 2025) - "T cell engager (TCE) CD3-bispecifics have improved the treatment of patients with B cell lymphomas leading to recent approvals of the CD20-targeted CD3 bispecifics including Glofitamab, Mosunetuzumab, and Epcoritamab for patients with relapsed, refractory diseases...Importantly, in a B-cell depleted PBMC-HT tumor co-culture assay, the tumor-killing potency of EVOLVE205 was improved by up to 70-fold compared to Glofitamab, and by over 1,000-fold compared to anti-CD20 mAbs such as Rituximab...It also demonstrates significant in vivo efficacy and a favorable developability profile. Our data indicated that EVOLVE205 with integrated CD2 co-stimulation offers greater efficacy and safety advantages compared to clinically available CD20-targeted TCE therapies and anti-CD20 mAbs for the treatment of B cell lymphomas and for B cell-mediated autoimmune diseases."

Trispecific • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

EVOLVE205, a Highly Potent 2:1 CD20-Targeted CD2 Co-Stimulatory T Cell Engager Engineered for the Treatment of B Cell Malignancies and B Cell Autoimmune Diseases (ASH 2024) - "Introduction : T cell engager (TCE) CD3-bispecifics have improved the treatment of patients with B cell lymphomas leading to recent approvals of the CD20-targeted CD3 bispecifics Glofitamab, Mosunetuzumab, and Epcoritamab for patients with relapsed, refractory diseases...Importantly, in a B-cell depleted PBMC-HT tumor co-culture assay, the tumor-killing potency of EVOLVE205 was improved by up to 60-fold compared to Glofitamab and Epcoritamab, and by over 1,000-fold compared to B-cell depleting therapeutics (BCDTs) such as Rituximab...Conclusion : CD20-targeted EVOLVE205 utilizes integrated CD2 costimulation to potently induce T cell activation and tumor killing without mediating significant cytokine release, and demonstrates significant in vivo efficacy, IgG-like pharmacokinetics, and a favorable developability profile. These features of EVOLVE205 appear to offer efficacy and safety advantages compared to clinically available CD20-targeted TCE therapies and BCDTs for the..."

IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD2

EVOLVE205, a highly potent 2:1 CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies and B cell autoimmune diseases (SITC 2024) - "Background T cell engager CD3-bispecifics have improved the treatment of patients with B cell lymphomas leading to recent approvals of the CD20-targeted CD3 bispecifics Glofitamab, Mosunetuzumab, and Epcoritamab for patients with relapsed, refractory diseases...Importantly, the tumor-killing potency of EVOLVE205 was improved by up to 60-fold compared to clinical benchmarks, and by over 1,000-fold compared to B cell depleting therapeutics (BCDTs) such as Rituximab...Conclusions CD2 costimulation integrated EVOLVE205 may provide sustained and potent T cell activation potentially to induce durable anti-tumor response in patients, while demonstrating good developability and favorable IgG-like pharmacokinetics in mice. EVOLVE205 is a highly differentiated CD20-targeted immunotherapy capable of providing deep and durable tissue and peripheral B cell depletion with favorable cytokine release profile compared to clinically available CD20-targeted TCE therapies and BCDTs for the..."

B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD2

EVOLVE205, a highly potent 2:1 CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies and B cell autoimmune diseases (SITC 2024) - "Background T cell engager CD3-bispecifics have improved the treatment of patients with B cell lymphomas leading to recent approvals of the CD20-targeted CD3 bispecifics Glofitamab, Mosunetuzumab, and Epcoritamab for patients with relapsed, refractory diseases...Importantly, the tumor-killing potency of EVOLVE205 was improved by up to 60-fold compared to clinical benchmarks, and by over 1,000-fold compared to B cell depleting therapeutics (BCDTs) such as Rituximab...Conclusions CD2 costimulation integrated EVOLVE205 may provide sustained and potent T cell activation potentially to induce durable anti-tumor response in patients, while demonstrating good developability and favorable IgG-like pharmacokinetics in mice. EVOLVE205 is a highly differentiated CD20-targeted immunotherapy capable of providing deep and durable tissue and peripheral B cell depletion with favorable cytokine release profile compared to clinically available CD20-targeted TCE therapies and BCDTs for the..."

B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD2

EVOLVE205, a highly potent 2:1 CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies and B cell autoimmune diseases (SITC 2024) - "Background T cell engager CD3-bispecifics have improved the treatment of patients with B cell lymphomas leading to recent approvals of the CD20-targeted CD3 bispecifics Glofitamab, Mosunetuzumab, and Epcoritamab for patients with relapsed, refractory diseases...Importantly, the tumor-killing potency of EVOLVE205 was improved by up to 60-fold compared to clinical benchmarks, and by over 1,000-fold compared to B cell depleting therapeutics (BCDTs) such as Rituximab...Conclusions CD2 costimulation integrated EVOLVE205 may provide sustained and potent T cell activation potentially to induce durable anti-tumor response in patients, while demonstrating good developability and favorable IgG-like pharmacokinetics in mice. EVOLVE205 is a highly differentiated CD20-targeted immunotherapy capable of providing deep and durable tissue and peripheral B cell depletion with favorable cytokine release profile compared to clinically available CD20-targeted TCE therapies and BCDTs for the..."

B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD2

EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) - "In an oral presentation (abstract #1137), researchers highlighted the discovery of EVOLVE205, a highly potent CD20-targeted CD2 co-stimulatory T cell engager designed in a 2:1 bispecific format. Presented data demonstrated EVOLVE205’s ability to drive stronger in vitro tumor killing activity compared to clinical benchmarks such as glofitamab without exaggerating cytokine release, and significant improvement in an in vivo efficacy model....'We are eager to translate these findings to the clinic and look forward to initiating first-in-human trials in 2025'."

New trial • Preclinical • Hematological Malignancies

EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) - "EvolveImmune Therapeutics...announced that new preclinical data highlighting EVOLVE, the company’s novel costimulatory T cell engager platform, will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 6-10, 2024, in Houston, Texas....In two poster presentations, EvolveImmune will highlight the latest preclinical safety and efficacy data for EVOLVE104, a novel multi-functional T cell engager with integrated CD2 co-stimulation which conditionally targets ULBP2/5/6....EvolveImmune continues to progress its chemistry, manufacturing, and control (CMC) activities for EVOLVE104, with the goal of advancing the program into the clinic in 2025....In addition, the company will deliver an oral presentation highlighting the discovery and profiling of EVOLVE205, a highly potent CD20-targeted CD2 co-stimulatory T cell engager designed in a 2:1 bispecific format."

Preclinical • Oncology • Solid Tumor